{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T15:48:44Z","timestamp":1747151324940,"version":"3.40.5"},"reference-count":28,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/02300"],"award-info":[{"award-number":["PI17\/02300"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Inflammatory bowel disease (IBD) recording validation among girls in the Spanish Primary Care Database For Pharmacoepidemiological Research (BIFAP).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this observational study, girls aged 9 to 18\u2009years registered in BIFAP between 2002 and 2016, were followed up until there was a recorded IBD diagnosis or a referral to specialist indicating IBD. Anonymized profiles were reviewed to retrieve diagnosis confirmation (a positive colonoscopy or biopsy, specialist, or physician's comments mentioning the IBD diagnosis) or discarding (negative procedure results, alternative diagnosis, or family history). \u201cpossible\u201d IBD were profiles missing that evidence, or had suspected IBD. The prescriptions of intestinal anti\u2010inflammatory agents, azatioprine, and mercaptopurine were collected. The prevalence of IBD was estimated after review.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Out of 480\u2009634 girls, 323 had a first ever recorded IBD, of which, 37.8% (N = 122) were \u201cconfirmed\u201d incident IBD diagnosis, 19.8% (N = 64) discarded and 38.7% (N = 125) \u201cpossible\u201d IBD. Additionally, 12 IBD records (3.7%) referred to prevalent IBD. Prescriptions were recorded in 94.3% (confirmed), 63.2% (possible), 83.3% (prevalent), and 3.1% (discarded) IBD cases. Prevalence was 52.83 \u201cconfirmed\u201d or 93.58\/10<jats:sup>5<\/jats:sup> girls when \u201cpossible\u201d IBD were added.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>For a third of the girls, the first recorded IBD included evidence confirming the diagnosis while most of those with missing evidence had treatment indicated for IBD. For research focused in sensitivity, an algorithm including \u201cpossible\u201d plus \u201cconfirmed\u201d episodes is recommended, whereas only \u201cconfirmed\u201d to guarantee higher predictive value. Prevalence suggests that IBD is not a rare disease among girls.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.5107","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T06:57:02Z","timestamp":1599202622000},"page":"1440-1449","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The recording and prevalence of Inflammatory bowel disease in girls' primary care medical Spanish records"],"prefix":"10.1002","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3576-8605","authenticated-orcid":false,"given":"Elisa","family":"Mart\u00edn\u2010Merino","sequence":"first","affiliation":[{"name":"Pharmacoepidemiology and Pharmacovigilance Department Spanish Agency for Medicines and Medical Devices (AEMPS)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5376-2549","authenticated-orcid":false,"given":"Mar","family":"Mart\u00edn\u2010P\u00e9rez","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Pharmacovigilance Department Spanish Agency for Medicines and Medical Devices (AEMPS)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Castillo\u2010Cano","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Pharmacovigilance Department Spanish Agency for Medicines and Medical Devices (AEMPS)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Montero\u2010Corominas","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Pharmacovigilance Department Spanish Agency for Medicines and Medical Devices (AEMPS)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"issue":"1","key":"e_1_2_9_2_1","first-page":"S3\u20139","article-title":"Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities","volume":"12","author":"Hanauer SB","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.03.022"},{"issue":"12","key":"e_1_2_9_4_1","first-page":"22529\u201342","article-title":"The epidemiology and risk factors of inflammatory bowel disease","volume":"8","author":"Ye Y","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/921730"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.228"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8553(05)70064-9"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22980"},{"key":"e_1_2_9_9_1","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Extension of indication variation assessment report. EMA\/CHMP\/668339\/2015 [Internet].2016Jun [cited 2020 Jan 27]. Retrieved fromhttps:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/cervarix-h-c-721-ii-0067-epar-assessment-report-variation_en.pdf"},{"key":"e_1_2_9_10_1","unstructured":"Grupo de TrabajoVPH2012de la Ponencia de Programa y Registro de Vacunaciones. Revisi\u00f3n del Programa de Vacunaci\u00f3n frente a Virus del Papiloma Humano en Espa\u00f1a Ponencia de Programa y Registro de Vacunaciones Grupo de trabajo VPH 2012 [Internet]. Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad Servicios Sociales e Igualdad; 2013 [cited 2019 Oct 10]. Report No.: Informes estudios e investigaci\u00f3n 2013. Retrieved fromhttps:\/\/www.mscbs.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/docs\/PapilomaVPH.pdf"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e31828134b3"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.06.030"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5006"},{"key":"e_1_2_9_14_1","unstructured":"Porcentaje de poblaci\u00f3n cubierta por el sistema sanitario publico. Encuesta Nacional de Salud. MSSSI\/INE. Indicadores clave [Internet]. Sistema Nacional de Salud;2018Jun. Retrieved fromhttp:\/\/inclasns.msssi.es\/main.html"},{"volume-title":"International Classification of Primary Care (ICPC)","year":"1987","author":"Lamberts H","key":"e_1_2_9_15_1"},{"key":"e_1_2_9_16_1","unstructured":"ICD\u2010ICD\u20109\u2010CM\u2010International Classification of Diseases Ninth Revision Clinical Modification. Published March 1 2019. Accessed December 12 2019.https:\/\/www.cdc.gov\/nchs\/icd\/icd9cm.htm."},{"key":"e_1_2_9_17_1","unstructured":"Pr\u00e1ctica Cl\u00ednica en Gastroenterolog\u00eda y Hepatolog\u00eda [Internet]. Vol. I. CTO Editorial;2015. Retrieved from:http:\/\/www.aegastro.es\/publicaciones\/publicaciones\u2010aeg\/practica\u2010clinica\u2010en\u2010gastroenterologia\u2010y\u2010hepatologia\/libro\u2010aeg\u2010practica\u2010clinica\u2010en\u2010gastroenterologia\u2010y\u2010hepatologia"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4124"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0842"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231333"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02564.x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-1074-z"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20021"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009735"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2015.03.001"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i25.2741"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa037"},{"key":"e_1_2_9_28_1","unstructured":"Mart\u00edn\u2010MerinoE. Molina InfanteJ. Mart\u00edn\u2010P\u00e9rezM. Montero\u2010CorominasD.. The recording and incidence of inflammatory bowel disease in girls' primary care medical Records in Spain. Suppl Abstr 35th Int Conf Pharmacoepidemiol Ther risk Manag Pharmacoepidemiol Drug Saf2019Aug 20; 28(S2):pp. 5\u2013586."},{"key":"e_1_2_9_29_1","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Product\u2010 or Population\u2010Specific Considerations IV: Paediatric population [Internet].2017Jul [cited 2018 Nov 13]. Retrieved fromhttps:\/\/www.ema.europa.eu\/documents\/scientific\u2010guideline\/draft\u2010guideline\u2010good\u2010pharmacovigilance\u2010practices\u2010gvp\u2010product\u2010population\u2010specific\u2010considerations\u2010iv_en.pdf"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5107","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.5107","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T06:10:31Z","timestamp":1692857431000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1002\/pds.5107"],"URL":"https:\/\/doi.org\/10.1002\/pds.5107","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2020,9,3]]},"assertion":[{"value":"2020-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}